Detalhe da pesquisa
1.
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 24(7): 798-810, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290468
2.
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
N Engl J Med
; 381(12): 1124-1135, 2019 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31150573
3.
Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 716-726, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857411
4.
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Int J Cancer
; 145(1): 295-305, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30613964
5.
Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
J Natl Compr Canc Netw
; 17(6): 703-710, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200353
6.
Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial.
Support Care Cancer
; 27(10): 3759-3767, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30712098
7.
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Lancet Oncol
; 19(4): 461-473, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29501366
8.
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
Hum Mol Genet
; 25(16): 3626-3634, 2016 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27436580
9.
Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT.
BMC Cancer
; 18(1): 114, 2018 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386004
10.
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
Int J Cancer
; 141(6): 1265-1276, 2017 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28577306
11.
Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
Radiology
; 282(1): 171-181, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27479804
12.
Prognostic value of primary gross tumor volume and standardized uptake value of 18F-FDG in PET/CT for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
Tumour Biol
; 39(7): 1010428317717843, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28671052
13.
Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
BMC Cancer
; 17(1): 567, 2017 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28836950
14.
Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma.
J Pathol
; 240(3): 329-340, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27538493
15.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Lancet Oncol
; 17(11): 1509-1520, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686945
16.
With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study.
BMC Cancer
; 16(1): 774, 2016 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717335
17.
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy.
BMC Cancer
; 15: 977, 2015 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675209
18.
A new T classification based on masticator space involvement in nasopharyngeal carcinoma: a study of 742 cases with magnetic resonance imaging.
BMC Cancer
; 14: 653, 2014 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25189623
19.
Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients.
J Biol Chem
; 287(42): 35484-35495, 2012 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22893706
20.
Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.
Am J Epidemiol
; 177(3): 242-50, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23255783